Stock AnalizBristol Myers Squibb (BMY) earnings for the quarter ended September 2026: EPS beats estimates
Bristol Myers Squibb reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at $1.35 against the analysts’ average forecast of $1.17, a beat of 15.2%.
Revenue for the quarter was $13.07 billion, up 6.9% from $12.22 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 1.4% on the first trading day after the report.
The last four quarters
Bristol Myers Squibb has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $1.35 | $1.17 | +15.2% | +7% | +1.4% |
| Jun 2026 | $2.04 | $1.60 | +27.7% | +6% | +3.5% |
| Mar 2026 | $1.58 | $1.42 | +11.2% | +3% | +1.1% |
| Dec 2025 | $1.26 | $1.20 | +4.6% | +1% | +7.6% |
What comes next
Analysts expect EPS of $1.50 for the next quarter on average and $6.44 for the fiscal year ending December 31, 2026.
The average analyst price target is $65.25, 3% above the current price of $63.43.
Valuation and score
Bristol Myers Squibb scores 2.4 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 14.1, and its intrinsic value under moderate assumptions is about 2% below the current market value. Full Bristol Myers Squibb analysis with 10 years of financials
Frequently asked questions
What was Bristol Myers Squibb’s EPS for the quarter ended September 2026?
$1.35 adjusted per share, against an analyst consensus of $1.17.
How much revenue did Bristol Myers Squibb report?
$13.07 billion, up 6.9% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.